Teva Pharmaceutical Industries (TEVA) Cash from Investing Activities (2016 - 2025)
Historic Cash from Investing Activities for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $165.0 million.
- Teva Pharmaceutical Industries' Cash from Investing Activities fell 1831.68% to $165.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $737.0 million, marking a year-over-year decrease of 694.44%. This contributed to the annual value of $737.0 million for FY2025, which is 694.44% down from last year.
- Per Teva Pharmaceutical Industries' latest filing, its Cash from Investing Activities stood at $165.0 million for Q4 2025, which was down 1831.68% from $135.0 million recorded in Q3 2025.
- Over the past 5 years, Teva Pharmaceutical Industries' Cash from Investing Activities peaked at $508.0 million during Q1 2021, and registered a low of $135.0 million during Q3 2025.
- Its 5-year average for Cash from Investing Activities is $233.8 million, with a median of $192.5 million in 2023.
- Its Cash from Investing Activities has fluctuated over the past 5 years, first soared by 10158.73% in 2021, then plummeted by 6830.71% in 2022.
- Over the past 5 years, Teva Pharmaceutical Industries' Cash from Investing Activities (Quarter) stood at $246.0 million in 2021, then tumbled by 31.71% to $168.0 million in 2022, then soared by 79.17% to $301.0 million in 2023, then plummeted by 32.89% to $202.0 million in 2024, then decreased by 18.32% to $165.0 million in 2025.
- Its Cash from Investing Activities stands at $165.0 million for Q4 2025, versus $135.0 million for Q3 2025 and $236.0 million for Q2 2025.